F11R and ductal breast carcinoma in situ: This study provides the first evidence that JAM-A is upregulated in human DCIS and can be successfully targeted in in vivo DCIS models to achieve functional reductions in tumor progression alongside signaling alterations which may themselves be pharmacologically targetable.